Torrent Pharmaceuticals Issues Anagrelide Recall

December 9, 2020 – Torrent Pharmaceuticals has voluntarily recalled one lot of Anagrelide Capsules, USP, following the product’s failure in a dissolution test that is part of routine quality testing.

Anagrelide is used to treat thrombocytopenia (blood clots). When it fails to dissolve properly, this can cause problems with the level of medication available in the body. This can put seriously ill patients at increased risk of blood clotting and life-threatening events such as heart attack and stroke. As of the date of the recall, Torrent Pharmaceuticals has not received any reports of adverse events related to the affected product.

Patients should contact a healthcare provider or pharmacist prior to stopping treatment with anagrelide, as the risk of stopping the medication may outweigh the risk of continuing treatment. For medical questions related to the recall, consumers can contact Torrent Pharmaceuticals at 1-800-912-9561 or at Medinfo.Torrent@apcerls.com. Patients should contact their health provider if they’ve experienced any issues that may be related to using the recalled product. Adverse events can also be reported to Torrent Pharmaceuticals and the FDA’s MedWatch program. For general questions about returning the recalled product, consumers should contact Qualanex at 1-888-424-4340.

The full recall announcement can be found on the FDA's website.

There is no member impact through Benecard Central Fill.